Biotechnology News and Research

RSS

Altered state physiology drug development platform to treat an array of human conditions

David H. Fater, CEO of Vicor Technologies, Inc., today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.

1 Oct 2009

Biology and geography scientists explain the spread of HIV-1 epidemic in Africa

Scientists studying biology and geography may seem worlds apart, but together they have answered a question that has defied explanation about the spread of the HIV-1 epidemic in Africa.

1 Oct 2009

New medical breakthrough by Bioheart for treatment of patients with heart disorders

Bioheart, Inc. offers yet another medical breakthrough with the next-level stem cell treatment for cardiac patients. The stem cells aid in limiting damage due to a cardiac event and promote angiogenesis or formation of new blood vessels.

1 Oct 2009

Resverlogix RVX-208 exceeds expectations in Phase 1b/2a clinical trial

Resverlogix Corp. announced today that results from the Company's Phase 1b/2a clinical trial have met and exceeded expectations by successfully concluding the drug, RVX-208, is safe and tolerable. Most importantly RVX-208 has met its primary endpoint to increase the production of plasma ApoA-I, the key cardioprotective protein in high-density lipoprotein (HDL), often referred to as "good" cholesterol.

1 Oct 2009

Obama's turn to retake lead on health reform nears

President Obama's turn to step to the lead regarding the shape of health reform legislation is quickly approaching.

1 Oct 2009

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

Vertex Pharmaceuticals Incorporated today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes repayable no later than October 31, 2012 in the total amount of $155 million.

1 Oct 2009

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Ardea Biosciences, Inc. announced that it will present results from a Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the 2009 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

1 Oct 2009

Jagiellonian University to develop modern reagents for serological tests

Every year, 2 million patients in Poland are treated with blood and blood products. But only blood compatible with the recipient's blood type can be safely transfused.

1 Oct 2009

Update from BioCryst Pharmaceuticals regarding intravenous peramivir

BioCryst Pharmaceuticals, Inc. today announced that it has delivered a written response to the request for proposal (RFP) announced on September 21, 2009 from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA). BioCryst management intends to provide an update once the RFP process has reached a conclusion.

1 Oct 2009

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

1 Oct 2009

Swemed Sense oocyte aspiration needle available now for Australian customers

“Swemed Sense, with its unique characteristics, is an important part of our existing product portfolio in Europe, and is now available even to our Australian customers, Says Vitrolife's Vice President of Marketing and Sales, Nils Sellbom. Vitrolife have identified Australia as one of the key markets in the world and we have a office located in Melbourne. Approximately 67 000 fertility treatment cycles are conducted in Australia and New Zealand each year”

1 Oct 2009

Welichem announces filing of clinical trial application with Health Canada

Welichem Biotech Inc. (the "Company") announces the filing with Health Canada of a clinical trial application for its lead, anti-inflammatory drug WBI-1001. The application is for a 3-month, double blinded clinical trial in patients with chronic atopic dermatitis at three trial centres.

1 Oct 2009

U.S. patent for Idaho Technology’s high resolution nucleic acid melting techniques

Idaho Technology’s patent portfolio continues to grow as the U.S. Patent and Trademark Office granted the company U.S. Patent No. 7,582,429 relating to methods of performing genetic analysis in the presence of a double-stranded nucleic acid binding dye.

30 Sep 2009

CBR Pharma reports on M&A in the biopharmaceutical industry

The history of the pharmaceutical industry is closely linked to the business practices of the combination and purchase of corporations. From the creation of the combined entity of Warner-Lambert in 1955, to the purchase of Warner-Lambert by Pfizer in 2000, to the recent acquisition of Wyeth, pharmaceutical and biotech companies have expanded their pipelines, portfolios, and sales forces through mergers and acquisitions (M&A).

30 Sep 2009

Aphios awarded NIH grant to develop pathogen inactivation technology for blood products

Aphios Corporation today announced that it has been awarded a RC-1 Challenge grant (No. 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health’s (NIH) American Recovery and Reinvestment Act (ARRA) funds to develop a generally-applicable pathogen inactivation technology for blood products.

30 Sep 2009

Immunocellular Therapeutics' pilot study can help in early cancer detection

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today results from its pilot study evaluating the cancer detection abilities of one of its lead monoclonal antibody product candidates, ICT-109. Data from this study demonstrated that ICT-109 had a statistically significant ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets.

30 Sep 2009

LAB Research announces the closing of its rights offering

LAB Research Inc. ("LAB Research" or the "Company"), a Canadian-based global non-clinical contract research organization, today announced the successful closing of its previously announced rights offering (the "Rights Offering") for total gross proceeds of $14.2 million.

30 Sep 2009

FDA's Structured Product Labeling to be discussed

The Center for Business Intelligence (CBI) is pleased to announce the full agenda for their forum on FDA's Structured Product Labeling (SPL R4). The inaugural program will be chaired by Theresa Brunone, Assistant Director, GlaxoSmithKline. The conference will take place in Washington, DC, on December 8-9, 2009.

30 Sep 2009

Polymedix commences Phase 1B study of novel anticoagulant reversing agent

PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).

30 Sep 2009

SATAI invests $1.045 million in Azaya Therapeutics

SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the commercialization of Azaya’s proprietary Protein Stabilized Nanoparticle (PSN) technology platform to produce targeted, safer and more effective formulations of chemotherapy pharmaceuticals for the treatment of cancer.

30 Sep 2009